Answers are grounded in this paper and cite their sources.
This study utilizes an all-payer database to compare 90-d and 1-year outcomes between marijuana and non-marijuana users undergoing total hip arthroplasty (THA). The primary aim of this study focused on 90-d and 1-year opioid consumption among marijuana users and non-users who underwent THA. Our secondary aim focused on comparing 90-d and 1-year rates of readmissions, revisions and adverse events between the two groups. A retrospective review was performed in the Mariner Database for all primary THA patients from 2010 to 2018. Marijuana users were identified utilizing International Classification of Diseases (ICD) 9 and 10 codes and matched 1:1 to non-marijuana users on age, sex, Charlson Comorbidity Index (CCI), obesity, alcohol, tobacco, illicit drug use, history of drug abuse, and presence of psychiatric history. This yielded a total of 1654 patients in each group. The 90-d and 1-year outcomes included opioid consumption, episode of care costs, readmissions, revisions, and complications. Chi-square was employed to assess categorical variables, while t-tests were employed for continuous variables. There was no difference in opioid consumption among marijuana users and non-marijuana users who underwent a THA. Marijuana use was associated with lower 90-d costs of care when compared with non-marijuana users. Marijuana users had higher rates of hip dislocation within 90 d and 1 year of surgery. Marijuana use is associated with higher 90-d and 1-year dislocation rates. THA recipients who use marijuana should be counseled concerning this increased risk. Prospective randomized control trials are needed to verify the results of this study.
No takes yet. Share an insight, caveat, or question.
Gwam et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: